Seres Therapeutics Grants Stock Options to New Employees
News related to:Seres Therapeutics, Inc · 1 min read
CAMBRIDGE, Mass., Sept. 08, 2026 /CourierPR/ -- Seres Therapeutics, a biotechnology company developing live biotherapeutics to address unmet needs in oncology and inflammatory diseases, recently announced the grant of inducement equity awards to two new employees. On September 4, 2026, the Compensation and Talent Committee of the company’s board of directors issued stock options to purchase a total of 4,200 shares of the company’s common stock to these new hires.
These equity grants are part of the company’s 2022 Employment Inducement Award Plan, which is specifically designed to attract new talent. The terms of the grant state that the options have an exercise price of $5.72 per share. The stock options will vest in phases, with 25% vesting on the first anniversary of the individual’s date of hire, and 6.25% vesting upon the completion of each three full months of service thereafter.
The Inducement Plan was adopted by the board of directors in December 2022, and its primary purpose is to provide equity awards to new employees as an inducement to enter into employment with Seres, in compliance with Nasdaq Listing Rule 5635(c)(4). This initiative underscores the company’s commitment to fostering a robust talent pipeline and supporting the growth of its workforce.
Seres Therapeutics, based in the US, continues to focus on its mission to innovate in the field of live biotherapeutics. The company’s primary focus is on developing products that can modulate host function to protect and improve mucosal epithelial barrier integrity, induce immune homeostasis and tolerance, and prevent the colonization and overgrowth of pathogens in the gastrointestinal tract. With this latest move, the company aims to further its research and development efforts, ensuring it can continue to bring innovative solutions to the market.
The inducement equity grants are seen as a strategic step to attract and retain highly skilled professionals, contributing to the company’s ongoing success and innovation in the biotechnology sector.